Multiple generic versions of UCB’s €1.13bn ($1.25bn) Vimpat (lacosamide) tablets have been approved by the US Food and Drug Administration in all four strengths after the sole patent shielding the branded treatment of seizures expired.
The end of US reissued patent RE38,551’s term on 17 March has resulted in eight simultaneous ANDA approvals for lacosamide 50mg, 100mg, 150mg, and 200mg
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?